"alpha-Synuclein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synuclein that is a major component of LEWY BODIES that plays a role in neurodegeneration and neuroprotection.
Descriptor ID |
D051844
|
MeSH Number(s) |
D12.776.631.860.500 D12.776.637.500
|
Concept/Terms |
alpha-Synuclein- alpha-Synuclein
- alpha Synuclein
- Non-AB Component of AD Amyloid Protein
- Non AB Component of AD Amyloid Protein
|
Below are MeSH descriptors whose meaning is more general than "alpha-Synuclein".
Below are MeSH descriptors whose meaning is more specific than "alpha-Synuclein".
This graph shows the total number of publications written about "alpha-Synuclein" by people in this website by year, and whether "alpha-Synuclein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 0 | 1 | 1 |
1999 | 0 | 1 | 1 |
2003 | 0 | 1 | 1 |
2004 | 0 | 1 | 1 |
2005 | 2 | 4 | 6 |
2006 | 2 | 1 | 3 |
2007 | 1 | 1 | 2 |
2008 | 0 | 2 | 2 |
2009 | 3 | 0 | 3 |
2010 | 3 | 3 | 6 |
2011 | 1 | 2 | 3 |
2012 | 5 | 0 | 5 |
2013 | 0 | 1 | 1 |
2014 | 2 | 2 | 4 |
2015 | 2 | 1 | 3 |
2016 | 2 | 1 | 3 |
2017 | 3 | 1 | 4 |
2018 | 9 | 0 | 9 |
2019 | 4 | 3 | 7 |
2020 | 2 | 2 | 4 |
2021 | 4 | 2 | 6 |
2022 | 2 | 1 | 3 |
2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "alpha-Synuclein" by people in Profiles.
-
Functional screening of lysosomal storage disorder genes identifies modifiers of alpha-synuclein neurotoxicity. PLoS Genet. 2023 05; 19(5):e1010760.
-
Microglia and astrocyte activation is region-dependent in the a-synuclein mouse model of Parkinson's disease. Glia. 2023 Mar; 71(3):571-587.
-
Trial of Prasinezumab in Early-Stage Parkinson's Disease. N Engl J Med. 2022 08 04; 387(5):421-432.
-
Slowing Parkinson's Disease Progression with Vaccination and Other Immunotherapies. CNS Drugs. 2022 04; 36(4):327-343.
-
1-Indanone and 1,3-indandione Derivatives as Ligands for Misfolded a-Synuclein Aggregates. ChemMedChem. 2022 01 19; 17(2):e202100611.
-
Parkinson's Disease Genetics and Pathophysiology. Annu Rev Neurosci. 2021 07 08; 44:87-108.
-
Light-Controlled Tyrosine Nitration of Proteins. Angew Chem Int Ed Engl. 2021 06 07; 60(24):13414-13422.
-
Proteomic Profiling of the Substantia Nigra to Identify Determinants of Lewy Body Pathology and Dopaminergic Neuronal Loss. J Proteome Res. 2021 05 07; 20(5):2266-2282.
-
Cycad Genotoxin Methylazoxymethanol Disrupts the Brain Ubiquitin-Proteasome Pathway, Tau and a-Synuclein, as Reported in ALS-PDC. J Neuropathol Exp Neurol. 2021 02 22; 80(3):286-288.
-
Dihydroquinazolines enhance 20S proteasome activity and induce degradation of a-synuclein, an intrinsically disordered protein associated with neurodegeneration. Bioorg Med Chem Lett. 2021 03 15; 36:127821.